Basen (第二型糖尿病治療藥物):開發平台分析及市場預測

本報告提供第2型糖尿病 Basen 的開發平台評估及市場預測，以市場特徵為首，評估分析競爭，開發平台等，再加上未來市場競爭等資訊，為您概述為以下內容。

1 目錄

1 目錄

• 1.1 表格一覽
• 1.2 圖表一覽

2 簡介

• 2.1 糖尿病
• 2.2 免疫學
• 2.2.1 患病率
• 2.2.2 死亡率
• 2.3 病因及危險因素
• 2.3.1 肥胖症
• 2.3.2 久坐的生活方式
• 2.3.3 家族病史及遺傳的特質
• 2.3.4 民族性
• 2.3.5 老年
• 2.4 經濟影響; 糖尿病
• 2.5 GlobalData 報告指南

3 第二型糖尿病: 市場特性

• 3.1 第二型糖尿病市場
• 3.2 第二型糖尿病市場 預測
• 3.3 第二型糖尿病市場: 促進成長要素及阻礙因素
• 3.3.1 促進成長要素;
• 3.3.2 阻礙因素

4 分類; 糖尿病

• 4.1 類型;糖尿病
• 4.1.1 第一型糖尿病
• 4.1.2 第二型糖尿病
• 4.1.3 妊娠性糖尿病
• 4.2 糖尿病 併發症
• 4.2.1 循環系統疾病
• 4.2.2 腎臟病
• 4.2.3 精神障礙
• 4.2.4 切除手術
• 4.2.5 視網膜症

5 進步; 抗糖尿病治療

6 治療藥物

• 6.1 胰島素
• 6.2 口服治療藥物
• 6.2.1 磺醯尿素類 (SUR)
• 6.2.2 雙胍類 (BGDs)
• 6.2.3 甲型糖解酵素抑制劑 (AGI)
• 6.2.4 Meglitinides
• 6.2.5 胰島素增敏劑 (TZDs)
• 6.2.6 DDP-4(DPP- 4) 抑制劑
• 6.2.7 口服並用療法
• 6.3 其他可注射藥物
• 6.3.1 Pramlintide
• 6.3.2 Exenatide
• 6.4 市場佔有率 (每一級) - 第二型糖尿病

7 Basen

• 7.1 簡介
• 7.2 作用機制
• 7.3 臨床研究
• 7.4 專利歷史記錄; Basen
• 7.5 銷售額影響因素; Basen
• 7.5.1 安全性優
• 7.5.2 潛在的有效性
• 7.5.3 美國及歐洲的糖尿病市場
• 7.5.4 專利到期 ; Basen
• 7.6 醫藥品評估
• 7.6.1 藥物的風險·效益評估
• 7.6.2 競爭的激烈程度
• 7.7 銷售額預期
• 7.7.1 目標患者群; Basen
• 7.7.2 投藥
• 7.7.3 市場滲透率
• 7.7.4 治療的年度成本
• 7.7.5 銷售額預測; Basen - 日本

8 糖尿病市場: 附錄

• 8.1 市場定義
• 8.2 簡稱一覽
• 8.3 調查方法
• 8.3.1 調查範圍
• 8.3.2 二級研究
• 8.3.3 預測
• 8.3.4 核准服藥的患者人數
• 8.3.5 治療藥物的淨市場滲透率
• 8.3.6 年度淨用藥量
• 8.3.7 治療的年度成本
• 8.4 治療藥物的銷售額預期模式
• 8.5 諮詢方式
• 8.6 免責聲明
• 8.7 資訊來源

表格一覽

1.1 表格一覽

• 表格 1: 糖尿病, 全球估計患者數 (20∼79歲的年齡群) (100萬人), 實際成果及預測
• 表格 2: 糖尿病, 前十名國家, 各患者數(100萬人), 實際成果及預測
• 表格 3: 糖尿病, 前十名國家, 最高醫療費 ($bn)
• 表格 4: 第二型糖尿病, 全球各銷售額主要上市藥 ($m)
• 表格 5: 第二型糖尿病, 全球主要 開發中產品 - 第三階段
• 表格 6: 糖尿病, 全球整體, 估計患者數, 實際成果及預測
• 表格 7: 肥胖率, 全球整體, 估計患者數 - 15歲以上的男性 (%)
• 表格 8: 糖尿病 治療藥物的演變
• 表格 9: Patent 認證
• 表格 10: 藥物的風險·效益評估
• 表格 11: Basen, 第二型糖尿病, 日本, 銷售額實際成果及預測 ($m)

圖表一覽

1.2 圖表一覽

• 圖 1: 糖尿病, 全球患病率比較 - 20∼79歲的年齡群 (%)
• 圖 2: 糖尿病, 全球患病率比較 - 20∼79歲的年齡群 (%), 預測
• 圖 3: 糖尿病, 全球死亡率
• 圖 4: 全球10大死因
• 圖 5: 第二型糖尿病, 全球整體, 市場規模預測 ($bn)
• 圖 6: 作用機制 ; 磺醯尿素類
• 圖 7: 作用機制 ; Biguanide, 胰島素增敏劑, 甲型糖解酵素抑制劑
• 圖 8: 作用機制 ; metohorumin 及 甲型糖解酵素抑制劑
• 圖 9: 作用機制 ; 胰島素增敏劑
• 圖 10: 作用機制 ; DPP IV 抑制劑
• 圖 11: 第二型糖尿病, 全球整體, 各級品牌市場佔有率 (%)
• 圖 12: Basen, 第二型糖尿病, 日本, 銷售額實際成果及預測 ($m)
• 圖 13: 服用這種藥物的患者

Abstract

Basen (Type 2 Diabetes) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Basen (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides Basen sales estimates for Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of Basen including historical sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Basen including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales forecast for 2002-2020 for Basen in Japan

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug's performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

TOC

1 Table of Contents

1 Table of Contents 2

• 1.1 List of Tables 3
• 1.2 List of Figures 3

2 Introduction 4

• 2.1 Diabetes 4
• 2.2 Epidemiology 4
• 2.2.1 Prevalence 4
• 2.2.2 Mortality 6
• 2.3 Etiology and Risk Factors 8
• 2.3.1 Obesity 8
• 2.3.2 Sedentary Lifestyle 8
• 2.3.3 Family History and Genetics 8
• 2.3.4 Ethnicity 8
• 2.3.5 Old Age 8
• 2.4 Economic Impact of Diabetes 8
• 2.5 GlobalData Report Guidance 10

3 Type 2 Diabetes: Market Characterization 11

• 3.1 Type 2 Diabetes Market 11
• 3.2 Type 2 Diabetes Market Forecasts 12
• 3.3 Type 2 Diabetes Market: Drivers and Restraints 13
• 3.3.1 Drivers 13
• 3.3.2 Restraints 14

4 Classification of Diabetes 15

• 4.1 Types of Diabetes 15
• 4.1.1 Type 1 Diabetes 15
• 4.1.2 Type 2 Diabetes 15
• 4.1.3 Gestational Diabetes 15
• 4.2 Diabetes Complications 15
• 4.2.1 Cardiovascular Disease 15
• 4.2.2 Nephropathy 16
• 4.2.3 Neuropathy 16
• 4.2.4 Amputation 16
• 4.2.5 Retinopathy 16

5 Evolution of Anti-Diabetic Treatments 17

6 Medications 18

• 6.1 Insulin 18
• 6.2 Oral Medications 18
• 6.2.1 Sulfonylureas (SUR) 18
• 6.2.2 Biguanides (BGDs) 18
• 6.2.3 Alpha-Glucosidase Inhibitors (AGI) 20
• 6.2.4 Meglitinides 20
• 6.2.5 Thiazolidinediones (TZDs) 21
• 6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 22
• 6.2.7 Oral Combination Therapy 22
• 6.3 Other Injectionable Medications 23
• 6.3.1 Pramlintide 23
• 6.3.2 Exenatide 23
• 6.4 Market Share as per Classes in Type 2 Diabetes 23

7 Basen 24

• 7.1 Introduction 24
• 7.2 Mechanism of Action 24
• 7.3 Clinical Studies 24
• 7.4 Approval History of Basen 24
• 7.5 Factors Affecting Sales of Basen 25
• 7.5.1 Better Safety Profile 25
• 7.5.2 Potential Benefits 25
• 7.5.3 Absence in the US and European Diabetes Market 25
• 7.5.4 Expired Patent of Basen 25
• 7.6 Drug Evaluation 25
• 7.6.1 Drug Risk Benefit Score 25
• 7.6.2 Intensity of Competition 26
• 7.7 Sales Estimates 26
• 7.7.1 Target Patient Pool for Basen 26
• 7.7.2 Dosing 26
• 7.7.3 Market Penetration 26
• 7.7.4 Annual Cost of Therapy 27
• 7.7.5 Sales Projection of Basen in Japan 28

8 Diabetes Market: Appendix 29

• 8.1 Market Definitions 29
• 8.2 List of Abberiviations 29
• 8.3 Research Methodology 30
• 8.3.1 Coverage 30
• 8.3.2 Secondary Research 30
• 8.3.3 Forecasting 30
• 8.3.4 Number of patients approved to take the drug 30
• 8.3.5 Net Penetration of Drug 31
• 8.3.6 Net Annual Dosing 31
• 8.3.7 Annual Cost of Therapy 31
• 8.4 Drug Sales Estimates Model 31
• 8.5 Contact Us 32
• 8.6 Disclaimer 32
• 8.7 Sources 32

List of Tables

1.1 List of Tables

• Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 4
• Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 6
• Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 9
• Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010 11
• Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 12
• Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 13
• Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 14
• Table 8: Diabetes Drugs Evolution 17
• Table 9: Patent Approval 24
• Table 10: Drug Risk Benefit Score 25
• Table 11: Basen, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2019 28

List of Figures

1.2 List of Figures

• Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 5
• Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 5
• Figure 3: Diabetes, World, Mortality, 2010 6
• Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 7
• Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020 12
• Figure 6: Mechanism of Action of Sulfonylureas 18
• Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 19
• Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 20
• Figure 9: Mechanism of Action of Thiazolidinediones 21
• Figure 10: Mechanism of Action of DPP IV Inhibitors 22
• Figure 11: Type 2 Diabetes, Global, Branded Market Share By Class (%), 2010 23
• Figure 12: Basen, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020 28
• Figure 13: Patients Approved for the Drug 31